+33 4 96 11 60 00
Success is Rewarded
News
12 January 2010 /
Technologies Médicales, Biotechnologie
Dedicated researchers with a reason to smile…
The latter part of 2009 saw the achievements of several local researchers rewarded, and they are now starting 2010 with a smile.
The Marseilles-based pharmaceutical company Trophos announced that their olesoxime compound for treating Amyotropic Lateral Sclerosis, also known as Lou Gehrig's disease, has been selected by "The Ones to Watch" review published by Thomson Reuters as one of the five most promising products entering phase 3.
The research into olesoxime is part of the MitoTarget collaborative project, for which the European Commission has awarded a grant of 6 million euro. Olesoxime has also been recognized as one of the 10 most promising neuroscience drugs in development by Windhover Information, the leading pharmaceutical and biotechnology analysts.
Another researcher in the spotlight is Professor Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix for Medical Research for his outstanding professional career. Among his many achievements, Professor Ben-Ari was the founder of the Mediterranean Neurobiological Institute (Inmed) in Marseilles.
In December, the Eloi Collery Grand Prix, one of the National Academy of Medicine's most prestigious prizes, was awarded to Professor Didier Raoult and his team for their work in the virology and bacteriology laboratory at the La Timone hospital in Marseilles. The resourcefulness of the team was again illustrated recently with their discovery of a new giant virus present in amoebae. Named the "Marseillevirus", it's the 5th largest viral genome to have been sequenced.
Lastly, and still in Marseilles, the recent inauguration of a new transplant and cell therapy unit (u2T) at the Institut Paoli Calmettes cancer centre marked a major event in the field of health.
We're betting that 2010 will see its own share of new awards and discoveries.
The Marseilles-based pharmaceutical company Trophos announced that their olesoxime compound for treating Amyotropic Lateral Sclerosis, also known as Lou Gehrig's disease, has been selected by "The Ones to Watch" review published by Thomson Reuters as one of the five most promising products entering phase 3.
The research into olesoxime is part of the MitoTarget collaborative project, for which the European Commission has awarded a grant of 6 million euro. Olesoxime has also been recognized as one of the 10 most promising neuroscience drugs in development by Windhover Information, the leading pharmaceutical and biotechnology analysts.
Another researcher in the spotlight is Professor Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix for Medical Research for his outstanding professional career. Among his many achievements, Professor Ben-Ari was the founder of the Mediterranean Neurobiological Institute (Inmed) in Marseilles.
In December, the Eloi Collery Grand Prix, one of the National Academy of Medicine's most prestigious prizes, was awarded to Professor Didier Raoult and his team for their work in the virology and bacteriology laboratory at the La Timone hospital in Marseilles. The resourcefulness of the team was again illustrated recently with their discovery of a new giant virus present in amoebae. Named the "Marseillevirus", it's the 5th largest viral genome to have been sequenced.
Lastly, and still in Marseilles, the recent inauguration of a new transplant and cell therapy unit (u2T) at the Institut Paoli Calmettes cancer centre marked a major event in the field of health.
We're betting that 2010 will see its own share of new awards and discoveries.
